ArticlePloS one2013
Rift Valley fever risk map model and seroprevalence in selected wild ungulates and camels from Kenya.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Transboundary Animal Diseases Associated With Cross-Border Camel Movement. A Systematic Review and Meta-Analysis.Transboundary and emerging diseases · 2026Pooled it
- Mechanistic models of Rift Valley fever virus transmission: A systematic review.PLoS neglected tropical diseases · 2022Pooled it
- Simulating the Transmission of Rift Valley Fever Virus via Raw Milk Consumption in Inter-Epidemic Periods.Viruses · 2026Article
- Investigation and response to rift valley fever outbreak in ruminant livestock from Ngoma District, eastern province of Rwanda, 2024.One health (Amsterdam, Netherlands) · 2026Article
- Review
- Rift Valley Fever Virus: An Overview of the Current Status of Diagnostics.Biomedicines · 2024Review
- Seroprevalence ofFrontiers in veterinary science · 2024Article
- Seroprevalence of Rift Valley Fever virus in one-humped camels (Camelus dromedaries) in Egypt.Tropical animal health and production · 2023Article
- Rift Valley Fever Virus-Infection, Pathogenesis and Host Immune Responses.Pathogens (Basel, Switzerland) · 2023Review
- Ecological and subject-level drivers of interepidemic Rift Valley fever virus exposure in humans and livestock in Northern Kenya.Scientific reports · 2023Article
- Natural hosts and animal models for Rift Valley fever phlebovirus.Frontiers in veterinary science · 2023Review
- Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes.Transboundary and emerging diseases · 2022Article
- Adaptation to a Multiplex Bead Assay and Seroprevalence to Rift Valley Fever N Protein: Nampula Province, Mozambique, 2013-2014.Journal of virology · 2022Article
- Evidence of co-exposure with Brucella spp, Coxiella burnetii, and Rift Valley fever virus among various species of wildlife in Kenya.PLoS neglected tropical diseases · 2022Article
- An unusually long Rift valley fever inter-epizootic period in Zambia: Evidence for enzootic virus circulation and risk for disease outbreak.PLoS neglected tropical diseases · 2022Article
- Identification and distribution of pathogens coinfecting with Brucella spp., Coxiella burnetii and Rift Valley fever virus in humans, livestock and wildlife.Zoonoses and public health · 2022Review
- Serological Evidence of Antibodies to Rift Valley Fever Virus in Wild and Domestic Animals in Bauchi State, Nigeria.Veterinary medicine international · 2022Article
- Rift Valley fever virus detection in susceptible hosts with special emphasis in insects.Scientific reports · 2021Article
- Serological evidence of single and mixed infections of Rift Valley fever virus, Brucella spp. and Coxiella burnetii in dromedary camels in Kenya.PLoS neglected tropical diseases · 2021Article
- Epidemiology and serological detection of Rift Valley Fever disease in farm animals in southern Egypt.The Onderstepoort journal of veterinary research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the first isolation of Rift Valley fever virus (RVFV) in the 1930s, there have been multiple epizootics and epidemics in animals and humans in sub-Saharan Africa. Prospective climate-based models have recently been developed that flag areas at risk of RVFV transmission in endemic regions based on key environmental indicators that precede Rift Valley fever (RVF) epizootics and epidemics. Although the timing and locations of human case data from the 2006-2007 RVF outbreak in Kenya have been compared to risk zones flagged by the model, seroprevalence of RVF antibodies in wildlife has not yet been analyzed in light of temporal and spatial predictions of RVF activity. Primarily wild ungulate serum samples from periods before, during, and after the 2006-2007 RVF epizootic were analyzed for the presence of RVFV IgM and/or IgG antibody. Results show an increase in RVF seropositivity from samples collected in 2007 (31.8%), compared to antibody prevalence observed from 2000-2006 (3.3%). After the epizootic, average RVF seropositivity diminished to 5% in samples collected from 2008-2009. Overlaying maps of modeled RVF risk assessments with sampling locations indicated positive RVF serology in several species of wild ungulate in or near areas flagged as being at risk for RVF. Our results establish the need to continue and expand sero-surveillance of wildlife species Kenya and elsewhere in the Horn of Africa to further calibrate and improve the RVF risk model, and better understand the dynamics of RVFV transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.